BioSpace News Archive

Precision Optics Corporation, Inc. announced operating results on an unaudited basis for its fourth quarter and fiscal year.

The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET -fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Fluent BioSciences announces the launch of a novel 100,000 cell product for 3′ single-cell RNA analysis.

National Association of Chronic Disease Directors CEO John W. Robitscher , MPH, participated in the 4th biannual Greater Horn Oncology Symposium (GHOS) held Sept. 23-25.

During a special event, The Feinstein Institutes for Medical Research, the research home of Northwell Health, and Governor Kathy Hochul announced the completion of a $35 million, 20,000-square-foot renovation project meant to energize future breakthroughs in bioelectronic medicine.

Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.

Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration Center for Drug Evaluation has approved a pivotal Phase III registration study that will bridge to Telix’s global Phase III ‘ZIRCON’ trial of TLX250-CDx, for the imaging of clear cell renal cell carcinoma with position emission tomography.

Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain.

Ascletis Pharma Inc. announces dosing of the first patient in the Phase IIb Expansion Cohort of subcutaneously administered PD-L1 antibody ASC22 for functional cure of chronic hepatitis B.

On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.